# **DEPARTMENT OF CHEMISTRY AND ENVIRONMENTAL SCIENCE**

## SPRING 2017 SEMINAR SERIES

Sponsored by: Purdue Pharma L.P. **Bristol-Myers Squibb Company** 

WEDNESDAY, APRIL 19, 2017 2:30 PM

**TIERNAN HALL ROOM 373** 

#### **GUEST SPEAKER**

Guodong Chen, Ph.D. **Bioanalytical and Discovery Analytical Sciences Pharmaceutical Candidate Optimization Research and Development Bristol-Myers Squibb Company Princeton**, New Jersey

# TOPIC

#### Mass Spectrometry in Biologics Discovery: Challenges and Opportunities

# ABSTRACT

Since the introduction of the first recombinant DNA-derived protein insulin in the 1980s and the launch of Interferons and Interleukins in the 1990s, biologics market has shown a healthy growth. This is largely due to advances in recombinant DNA technology that have provided the means to produce therapeutic proteins. Mass spectrometry is uniquely positioned to cope with additional challenges for the analysis of biologics, due to its analytical sensitivity, speed and specificity. This presentation will present current status and advancements in mass spectrometry characterization of biologics, including primary structural analysis and higher order structure characterization in drug discovery.

#### **BIOGRAPHY**

Dr. Guodong Chen has extensive pharmaceutical research experience in major pharmaceutical companies, including Eli Lilly, Schering-Plough and Bristol-Myers Squibb. Currently, he heads analytical/mass spectrometry group at Bristol-Myers Squibb central New Jersey site. He has over 75 research publications in peer-reviewed journals and book chapters, three edited/co-edited books on pharmaceutical and biopharmaceutical analysis, multiple patents on antibody

<text>